During the COVID-19 pandemic, patients with sickle cell disease (SCD) have been included in the "high risk" group of the population. This is due to their impaired immunity resulting from functional hyposplenism, systemic vasculopathy that predisposes them to end organ dysfunction, and a high risk of thrombosis (Ware et al, 2017).